Senseonics Sees Unusually High Options Volume (NYSE:SENS)

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) was the target of unusually large options trading activity on Monday. Investors acquired 4,425 call options on the company. This is an increase of approximately 63% compared to the average daily volume of 2,719 call options.

Insider Buying and Selling

In other Senseonics news, CEO Timothy T. Goodnow bought 315,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was acquired at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the acquisition, the chief executive officer now owns 11,310,355 shares in the company, valued at $3,506,210.05. This trade represents a 2.86 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the business's stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the acquisition, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Senseonics

Institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in shares of Senseonics in the 4th quarter worth approximately $26,000. HighTower Advisors LLC purchased a new position in Senseonics in the fourth quarter worth $32,000. Two Sigma Investments LP purchased a new position in Senseonics in the fourth quarter worth $36,000. Ridgecrest Wealth Partners LLC bought a new position in Senseonics in the 4th quarter valued at $60,000. Finally, Beck Mack & Oliver LLC purchased a new stake in shares of Senseonics during the 4th quarter valued at $79,000. 12.36% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several analysts recently issued reports on SENS shares. HC Wainwright reissued a "buy" rating and issued a $2.00 price target on shares of Senseonics in a research report on Wednesday. StockNews.com initiated coverage on shares of Senseonics in a report on Thursday, December 26th. They set a "sell" rating for the company.

Senseonics Stock Down 11.4 %

SENS traded down $0.08 during midday trading on Thursday, reaching $0.61. 12,145,356 shares of the company were exchanged, compared to its average volume of 14,727,012. Senseonics has a one year low of $0.25 and a one year high of $1.40. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company's fifty day moving average price is $0.86 and its 200 day moving average price is $0.53. The company has a market cap of $365.65 million, a price-to-earnings ratio of -4.72 and a beta of 1.17.

Senseonics (NYSE:SENS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same period in the previous year, the business earned ($0.07) earnings per share. As a group, analysts expect that Senseonics will post -0.14 EPS for the current year.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.